Otsuka to use IPO money to fund buyouts; Covagen closes Series A;

 @FierceBiotech: The Best of FierceBiotech 2010. Report | Follow @FierceBiotech

> Japan's Otsuka is reportedly telling investors that it will use the money raised from its IPO to fund the acquisition of drug businesses. Story

> Switzerland's Covagen says it closed a Series A financing round in which CHF 6.3 million was raised. Covagen release

Special Report: FierceBiotech's Top Writers in Biotech. Report

> Quintiles and London Genetics are teaming up on a new personalized medicines initiative. Quintiles release

> Merck says it is halting studies of a single dose of the HIV drug Isentress after pondering data demonstrating its inferiority to a twice-daily dose. Story

Special Report: The Top 10 Phase III Failures of 2010. Report

> Medicago announced an extension to its partnering agreement of July 2009 with Genopole. Medicago release

And Finally... By tweaking a gene, scientists say they were able to reverse the age-related decline of mice. Story

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.